Q1: What is the difference between indirect and direct radiolabeling?

Indirect labeling uses chelators (e.g., DFO, NOTA) conjugated to exosome surfaces for stable radiometal binding. Direct labeling uses lipophilic tracers (e.g., [ 89 Zr]Zr(oxinate) 4 , 99m Tc-HMPAO) that diffuse into exosomes without chemical modification. Selection depends on isotope, study duration, and labeling tolerance.

Q2: Which radionuclide is best for multi-day PET imaging?

89 Zr (t½ = 78.4 h) is preferred for long-term tracking due to its matched half-life with exosome biodistribution. For short-term studies, 64 Cu or 18 F may be more suitable depending on imaging window.

Q3: How is radiochemical purity ensured?

Radiochemical purity is assessed by TLC or SEC immediately post-labeling and after serum incubation. Free isotope is removed via SEC, filtration, or dialysis. Release criteria typically require >90% purity, with additional checks for in vivo instability.

Q4: Does radiolabeling affect exosome integrity?

Optimized, mild protocols are used to minimize structural or functional damage. Post-labeling integrity is verified by NTA, TEM, and optional uptake assays, with controlled specific activity to reduce radiolysis risk.

Q5: Do you support in vivo imaging or only labeling?

Both options are available. Clients may receive QC-validated radiolabeled exosomes or request full in vivo support, including dosing, SPECT/PET imaging, ROI analysis, and pharmacokinetic evaluation via imaging partners.

Q6: Which animal models and administration routes are supported?

Supported models include mice, rats, and rabbits. Common routes include IV, IP, SC, and targeted injections (e.g., intratumoral, intracranial), selected based on study design and biological target.

Exosome Radiolabeling Services - Creative Biostructure Exosome

Exosome radiolabeling enables highly sensitive SPECT/PET imaging for quantitative in vivo tracking of biodistribution, pharmacokinetics, and therapeutic behavior. Compared with optical methods, it provides deep-tissue penetration and absolute signal quantification. Creative Biostructure delivers end-to-end exosome radiolabeling services, including isotope selection, labeling optimization, purification, quality control, and imaging support. We apply tailored strategies such as chelator-based labeling, intraluminal labeling, and radioiodination to ensure stable, high-specific-activity, and reproducible imaging results.

What Is Exosome Radiolabeling for SPECT/PET Imaging

Exosome radiolabeling for SPECT/PET imaging refers to the incorporation of gamma- or positron-emitting radionuclides into or onto exosomes, enabling non-invasive detection of their distribution in living animals. Two principal radiolabeling strategies are used in contemporary EV research:

Indirect radiolabeling: A bifunctional chelator (e.g., DFO, NOTA, DOTA) is conjugated to exosome surface proteins or lipids, followed by coordination with metal radionuclides (e.g., ⁸⁹Zr, ⁶⁴Cu, ⁶⁸Ga).
Direct radiolabeling: Lipophilic radiotracers (e.g., [⁸⁹Zr]Zr(oxinate)₄, ^99mTc-HMPAO) passively diffuse across the exosome membrane and are retained in the lumen or membrane, without requiring chemical conjugation.

Why Radiolabeling Matters for In Vivo Exosome Tracking

Optical imaging modalities (fluorescence, bioluminescence) are constrained by tissue autofluorescence, photon scattering, and limited penetration depth (<1 mm), making them unsuitable for deep-tissue or whole-body biodistribution studies in vivo. Nuclear imaging overcomes these limitations:

Deep-tissue penetration: Gamma photons (SPECT) and 511-keV annihilation photons (PET) enable non-invasive whole-body imaging.
Absolute quantification: Regions of interest (ROIs) can be converted to %ID/g (percentage of injected dose per gram tissue) using calibration standards.
High sensitivity: Picomolar-to-femtomolar detection enables tracking of low-dose exosome administrations relevant to translational studies.
Temporal resolution: Longitudinal imaging in the same animal over hours to days reduces inter-animal variability and overall animal use.

89Zr-oxinate enters sEVs and releases zirconium, which binds internal proteins and nucleic acids for imaging. Figure 1. Intraluminal ⁸⁹Zr Radiolabeling Mechanism of Small Extracellular Vesicles (sEVs). (Khan A A, et al., 2022)

Our Advanced Exosome Radiolabeling Services for SPECT/PET

Creative Biostructure provides a full suite of radiolabeling services tailored to the isotope, exosome source, and imaging objective. Each project is scoped through a pre-labeling consultation to match the radionuclide and labeling chemistry to the preclinical question, the imaging modality (SPECT or PET), and the required temporal window.

Radionuclide and Labeling-Strategy Portfolio

Radionuclide	Imaging Modality	Half-Life	Key Labeling Method	Primary Applications	Special Considerations
^99mTc	SPECT	6.0 h	HMPAO, direct reduction	Acute biodistribution, organ uptake (liver/spleen)	Same-day imaging; low cost; widespread availability
¹¹¹In	SPECT	2.8 d	Oxine, DTPA	Multi-day SPECT tracking, ex vivo biodistribution	Long half-life; potential for ¹¹¹In-transferrin transchelation
¹²⁴I	PET	4.2 d	Bolton-Hunter, IODO-GEN	Multi-day PET; thyroid blocking required	Block thyroid with KI; ¹²⁴I also emits gamma
⁸⁹Zr	PET	78.4 h	DFO-chelation, [⁸⁹Zr]Zr(oxinate)4	Multi-day PET, stem cell-derived exosomes	DFO conjugation mild; oxinate method is direct and fast
⁶⁴Cu	PET	12.7 h	NOTA, DOTA	Same-day to next-day PET; theranostic pairing	⁶⁴Cu has β+ fraction ~17.6%; NOTA preferred for stability
¹⁸F	PET	109.8 min	ALT, SFB, click chemistry	High-resolution small-animal PET	Requires rapid conjugation; ultra-high sensitivity

Labeling Strategies We Offer

Indirect chelation labeling (DFO-⁸⁹Zr, NOTA-⁶⁴Cu, DOTA-⁶⁸Ga): Surface conjugation of bifunctional chelators to exosome proteins or amino lipids, followed by radiometal coordination. Optimized conditions preserve vesicle integrity and achieve >90% radiochemical purity.
Direct intraluminal radiolabeling ([⁸⁹Zr]Zr(oxinate)₄): Passive diffusion of the lipophilic ⁸⁹Zr-oxinate complex into the exosome lumen, requiring no chemical conjugation and completing within 15-30 min at room temperature.
^99mTc-HMPAO radiolabeling: Reduction of ^99mTc-pertechnetate with stannous chloride in the presence of HMPAO, followed by incubation with exosomes. The lipophilic ^99mTc-HMPAO complex crosses the membrane and is retained.
Radioiodination (¹²⁴I/¹²⁵I): Indirect labeling of surface tyrosine residues using Bolton-Hunter reagent or IODO-GEN oxidation. Suitable for PET (¹²⁴I) and SPECT/ex vivo (¹²⁵I) imaging.
Dual-isotope labeling: Concurrent or sequential incorporation of two isotopes (e.g., ^99mTc for SPECT and ⁸⁹Zr for PET) for cross-validation or multi-parameter tracking.
Custom radiochemistry: For novel isotopes, chelators, or click-chemistry approaches, we perform feasibility assessment and protocol optimization using the client's exosome system.

Our End-to-End Radiolabeling Workflow

Consultation & isotope selection: Define study goals and select optimal radionuclide and labeling strategy based on exosome source and imaging needs.
Exosome characterization: Pre-labeling assessment of size/concentration (NTA), morphology (TEM), and markers (CD9/CD63/CD81).
Radiolabeling reaction: Isotope-specific labeling under ALARA-compliant, shielded conditions to preserve exosome integrity.
Purification & RCP analysis: Removal of free isotope via SEC/filtration/dialysis, with radiochemical yield and purity confirmation (TLC/SEC).
QC & stability testing: Evaluation of particle integrity and in vitro stability; optional sterility and endotoxin testing for in vivo use.
In vivo support & reporting: Guidance on dosing, imaging, ROI analysis, %ID/g quantification, and structured data reporting.

Six-step exosome radiolabeling workflow for SPECT/PET imaging from isotope selection to in vivo quantitative analysis. Figure 1. Exosome Radiolabeling Workflow for SPECT/PET Imaging. (Creative Biostructure)

Comprehensive Quality Control and Characterization

Labeling efficiency: Evaluated by TLC or SEC with fraction analysis and radioactivity measurement.
Radiochemical purity (RCP): Typically >90% at release, with follow-up assessment in serum to verify short-term stability.
Particle size & concentration: NTA pre- and post-labeling to monitor size distribution changes and aggregation risk.
Morphology: TEM/cryo-EM used to confirm structural integrity of vesicles after labeling.
Specific activity: Reported as activity per particle number or protein amount to support dosing.
In vitro stability: Serum incubation at physiological temperature with time-course monitoring of label retention.
Sterility & endotoxin: Standard testing applied for preparations intended for in vivo use.

Applications (Research Use Only)

Whole-body biodistribution studies of systemically administered exosomes in mice, rats, or larger animal models.
Organ tropism mapping (liver, spleen, lung, kidney, brain, tumor) to support dose and route selection.
Pharmacokinetic profiling, including blood half-life, AUC, and clearance pathways (renal, hepatobiliary).
Comparative biodistribution of engineered vs. native exosomes (e.g., modified, loaded, or ligand-decorated).
Longitudinal tracking of the same animal over days to weeks.
Specificity evaluation using blocking or competitive uptake studies.
Translational pharmacokinetic studies supporting IND-enabling preclinical packages.

What Deliverables Will You Receive

Deliverable	Details
Radiolabeled product	Sterile, imaging-ready radiolabeled exosomes (defined activity/volume)
Radiolabeling report	Isotope, labeling efficiency, RCP (0 h & stability check), specific activity
QC characterization	NTA (size/concentration), optional TEM and marker validation
Purity verification	TLC/SEC-based radiochemical purity data
Imaging data (if applicable)	Raw DICOM/NIfTI files and %ID/g ROI quantification
Technical documentation	Full methods, results summary, and handling/storage guidance
Optional analysis	Pharmacokinetic modeling (AUC, half-life, compartment analysis)

How to Get Started

Clients may provide purified exosomes or request upstream isolation and production support. Project initiation follows a streamlined workflow:

Share your exosome source, target radionuclide (or request recommendation), imaging modality, and animal model.
Our team assesses feasibility, advises on isotope logistics, and provides a tailored proposal with timeline and cost.
Upon approval, we perform radiolabeling and QC under controlled conditions and deliver the radiolabeled product with full documentation and imaging support as needed.

Why Choose Creative Biostructure

Radiochemistry expertise: Extensive experience with ^99mTc, ⁸⁹Zr, ⁶⁴Cu, ¹²⁴I, and ¹⁸F labeling of extracellular vesicles.
Rigorous QC standards: Multi-parameter release criteria (RCP >90%, size stability, morphology) ensure reproducible data quality.
Isotope-flexible design: Support for SPECT and PET tracers with guidance on optimal isotope selection.
Translational focus: Workflows aligned with GLP/GMP principles to support progression toward clinical studies.
Integrated services: Radiolabeling combined with exosome isolation, characterization, and engineering in one workflow.
Regulatory compliance: Full adherence to radiation safety standards, with support for institutional approvals when required.

Case Study

Case: Tc-99m Radiolabeled Exosome SPECT Imaging (UCMSC-EVs)

Background

UCMSC-derived exosomes were radiolabeled with Tc-99m to enable quantitative SPECT imaging for in vivo biodistribution and pharmacokinetic analysis.

Methods

Labeling: Direct SnCl₂-mediated Tc-99m surface radiolabeling
Model: BALB/c mice (IV injection)
Imaging: SPECT/CT + ex vivo gamma counting
Analysis: iTLC, HPLC, and two-compartment PK modeling

Results

Radiolabeling: ~52% yield, >99% purity
Stability: Maintained up to 24 h in serum
Integrity: No significant change in size or exosomal markers
Biodistribution: Predominant uptake in liver and spleen
PK: Rapid distribution (0.85 min) and elimination (~25 min)
Clearance: Primarily urinary excretion

Conclusion

Tc-99m labeling enables stable, quantitative tracking of exosomes in vivo, supporting reliable biodistribution and pharmacokinetic assessment for translational research.

SPECT/CT shows Tc-99m exosomes accumulate in liver and spleen with urinary clearance and low thyroid uptake. Figure 3. Representative SPECT/CT imaging and quantitative biodistribution of Tc-99m-labeled UCMSC-derived exosomes compared with free pertechnetate control over time. Radiolabeled exosomes show predominant accumulation in liver and spleen, minimal thyroid/stomach signal, and urinary clearance. (Chung Y H, et al., 2024)

Ready to quantify your exosome biodistribution with SPECT or PET imaging? Contact us to discuss isotope selection, radiolabeling strategy, imaging coordination, and a customized project plan.

References

Khan A A, Man F, Faruqu F N, et al. PET imaging of small extracellular vesicles via [89Zr] Zr (oxinate) 4 direct radiolabeling. Bioconjugate Chemistry. 2022, 33(3): 473-485.
Chung Y H, Ho Y P, Farn S S, et al. In vivo SPECT imaging of Tc-99m radiolabeled exosomes from human umbilical-cord derived mesenchymal stem cells in small animals. Biomedical Journal. 2024, 47(5): 100721.
Li J, Li C, Zheng H, et al. Biodistribution studies of 89Zr-labeled stem cell-derived exosomes using PET imaging. Applied Radiation and Isotopes. 2025, 225: 112000.

Frequently Asked Questions

For any inquiries, our support team is ready to help you get technical support for your research and maximize your experience with Creative Biostructure.

Related Services